CellWell record HH-575962
Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib
Piotr Kawczak; Tomasz Bączek
2026
In plain language
Review finds anti-EGFR antibody therapy remains a cornerstone for RAS wild-type metastatic colorectal cancer, and BRAF plus EGFR blockade improved overall survival versus chemotherapy in BRAF V600E-mutant disease.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-575962
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.